Comparision for remimazolam and midazolam in upper gastrointestinal endoscopy in elderly patients: A randomized controlled trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007274

Enrollment

120

Registered

2022-05-13

Start date

2022-09-01

Completion date

Unknown

Last updated

2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : When performing upper gastrointestinal endoscopy, the initial dose of sedative will be given to the both group. (group A: remimazolam 5.0mg, group B: midazolam 2.0mg) Measure the MOAA/S score p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 65 years old or older ASA physical status of I, II, III BMI 18 to 30 kg/m2 Those who agreed to participate in this study Patients who are scheduled for a sedative upper gastrointestinal endoscopy of less than 30 minutes

Exclusion criteria

Exclusion criteria: Patients with previous gastrointestinal surgery (except for appendectomy and cholecystectomy) Patients with renal dysfunction or hypotension or uncontrolled hypertension Patients with hepatic dysfundcion or history of liver cirrhosis Patients taking any of the following medications within the past 3 months (benzodiazepines, opioids, propofol, lidocaine) Others, who are judged inappropriate by the research director

Design outcomes

Primary

Measure	Time frame
sedation success rate	—

Secondary

Measure	Time frame
recovery time to sedation	—

Countries

Korea, Republic of

Contacts

Public ContactGil Ho Lee

Ajou University Hospital

micorie@hanmail.net+82-31-219-5654

Outcome results